Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

244.99 +1.66 (+0.68%)
Official Closing Price Updated: 4:10 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
News headline image
Warren Buffett's Granddaughter Claimed He Cut Her Off And She Couldn't Afford Health Insurance: 'He Disowned My Twin Sister And Myself' ↗
 
Via Benzinga
News headline image
2 Stocks to Buy if There Is a Market Crash in 2025 ↗
Via The Motley Fool
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
Via The Motley Fool
Topics Stocks
News headline image
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years ↗
On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz). 
Via Benzinga
News headline image
(JNJ) - Analyzing Johnson & Johnson's Short Interest ↗
 
Via Benzinga
News headline image
Kenvue's Q4 Sales Miss, Margins Improve ↗
Kenvue posted mixed Q4 earnings, with in-line EPS but revenue below estimates, driven by challenges in its Skin Health and Beauty segment. 
Via The Motley Fool
Topics Earnings
News headline image
Is Johnson & Johnson Stock a Buy? ↗
Via The Motley Fool
News headline image
Johnson & Johnson's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
News headline image
What To Expect From Eli Lilly’s (LLY) Q4 Earnings
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect. 
Via StockStory
News headline image
Can Biotech Stocks Survive The Precarious Macro? ↗
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows. 
Via Talk Markets
Topics Stocks / Equities World Trade
News headline image
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp? 
Via MarketBeat
News headline image
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around? ↗
Via The Motley Fool
News headline image
Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock? ↗
Via The Motley Fool
News headline image
The Dogs Of The Dow 2025 ↗
The Dogs of the Dow is an investing strategy well-known to retail and institutional investors. 
Via Talk Markets
Topics Stocks Stocks / Equities
News headline image
Johnson & Johnson (NYSE:JNJ) Posts Q4 Sales In Line With Estimates
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 5.3% year on year to $22.52 billion. Its non-GAAP profit of $2.04 per... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders ↗
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
News headline image
Starbucks To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Marjorie Taylor Greene Loads Up On Meta, Amazon, Tesla, Nvidia And Other Stocks As Donald Trump's New Equations With Big Tech Leaders Sets Stage For Growth: What Is At Stake? ↗
U.S. House Representative Marjorie Taylor Greene has disclosed new trades as Donald Trump's equations evolves with Big Tech leaders. 
Via Benzinga
Topics Government
News headline image
Georgia Rep. Marjorie Taylor Greene Bought Up to $45K Worth of Johnson & Johnson Stock ↗
 
Via Benzinga
News headline image
3 Stocks Upgraded by Bank of America – Here's Why They're Bullish
Bank of America analysts have recently shifted their views on these three stocks, leaving investors with a few points to consider. 
Via MarketBeat
News headline image
McDonald's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Why Traders Are Buying the Dip on Johnson & Johnson Stock
Shares of Johnson & Johnson stock have declined by 11.5% in the quarter, and markets are calling for a bottom and rally here. 
Via MarketBeat
News headline image
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024 ↗
Via The Motley Fool
Topics Stocks
News headline image
Abbott Laboratories Will Outperform Healthcare Stocks in 2025
Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026. 
Via MarketBeat
News headline image
5 of the Safest High-Yield Dividend Stocks You Can Confidently Buy for 2025 ↗
Five magnificent income stocks -- sporting an average yield of 4.26% -- can pad investors' pocketbooks in the new year (and well beyond). 
Via The Motley Fool
News headline image
Stocks Going Ex Dividend In February 2025 ↗
This article features a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors 
Via Talk Markets
Topics Stocks / Equities
News headline image
Up About 62% in a Year, Can Intuitive Surgical Stock Keep Soaring? ↗
Via The Motley Fool
News headline image
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst ↗
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments. 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.